½ÃÀ庸°í¼­
»óǰÄÚµå
1586739

¼¼°èÀÇ ¿µ»ó À¯µµ Ä¡·á ½ÃÀå(2024-2029³â)

Image-guided Therapy Market, Global, 2024-2029

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Frost & Sullivan | ÆäÀÌÁö Á¤º¸: ¿µ¹® 107 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

Àúħ½ÀÀû ¼ö¼ú¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿Í ¿Ü·¡È¯ÀÚ ½Ã¼³¿¡¼­ ´çÀÏ ¼ö¼úÀÌ ±ÞÁõÇϸ鼭 Çõ½ÅÀû ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù.

¿µ»óÀ¯µµÄ¡·á(IGT) ½ÃÀåÀº Àúħ½ÀÀû Ä¡·á¿¡ ´ëÇÑ ¼±È£µµ Áõ°¡, ¸ÖƼ¸ð´Þ ¿µ»óÁø´Ü ±â¼ú ¹ßÀü, ÀΰøÁö´É, ´õ ³ªÀº ÀÓ»ó°á°ú¸¦ °¡´ÉÇÏ°Ô ÇÏ´Â ¼ÒÇÁÆ®¿þ¾î ¼Ö·ç¼ÇÀÇ »ç¿ë, ¾Ï Ä¡·á¿¡¼­ Á¤¹ÐÀÇ·á¿¡ ´ëÇÑ ³ôÀº ¼ö¿ä·Î ÀÎÇØ ºü¸£°Ô ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, IGT ½ÃÀåÀº Á¾¾çÇÐ, ½ÉÀåÇÐ, ½Å°æ¿Ü°ú, Á¤Çü¿Ü°ú, ºñ´¢±â°ú ½Ã¼ú¿¡¼­ MRI, CT, ºÐÀÚ ¿µ»ó, ÃÊÀ½ÆÄ, ÁßÀçÀû ¿¢½º·¹ÀÌÀÇ ±â¼ú Çõ½ÅÀÇ ¿µÇâÀ» ¹Þ°í ÀÖ½À´Ï´Ù. ¾Õ¼­ ¾ð±ÞÇÑ ÀÇ·á ¿µ»ó Áø´Ü ¾ç½Ä°ú ³»ºñ°ÔÀÌ¼Ç ½Ã½ºÅÛ ¹× ·Îº¿ °øÇÐÀÇ ÅëÇÕÀº ¿Ü°ú ¼ö¼ú¿¡¼­ ´õ ³ôÀº Á¤¹Ðµµ¿Í Á¤È®¼ºÀ» °¡´ÉÇÏ°Ô Çß½À´Ï´Ù.

Frost & SullivanÀº IGT°¡ ÇâÈÄ 5³â°£ ¾ÈÁ¤ÀûÀÎ ¼ºÀå¼¼¸¦ À¯ÁöÇÒ °ÍÀ¸·Î ¿¹»óÇϰí ÀÖÀ¸¸ç, ±× ¿øµ¿·ÂÀº ½ÃÀå È®´ëÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¿¬±¸°³¹ß¿¡ ´ëÇÑ ÁöÃâ°ú ÅõÀÚ Áõ°¡·Î ÀÎÇÑ °ÍÀ¸·Î º¸°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ Frost & SullivanÀº ÃÖ¼Òħ½À ¼ö¼úÀÌ ±âÁ¸ ¼ö¼úº¸´Ù ³ôÀº º¸±Þ·üÀ» º¸À̸ç IGT ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹ÃøÇß½À´Ï´Ù.

¿¬±¸ ±â°£Àº 2022-2029³â, ±âÁØ ¿¬µµ´Â 2024³â, ¿¹Ãø ±â°£Àº 2025-2029³âÀÔ´Ï´Ù. ÀÌ º¸°í¼­´Â ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç ¹× ±âŸ ¼¼°è ½ÃÀåÀ» ºÐ¼®ÇÏ¿© ÇöÀç ½Ã³ª¸®¿À, ÃËÁø ¹× ¾ïÁ¦¿äÀÎ, Ãֽбâ¼ú, ÁÖ¸ñÇÒ ¸¸ÇÑ ÁøÃâ±â¾÷¿¡ ÃÊÁ¡À» ¸ÂÃß¾ú½À´Ï´Ù.

Frost & SullivanÀº IGT ½ÃÀåÀ» ´ÙÀ½°ú °°Àº ¹üÁÖ·Î ºÐ·ùÇÕ´Ï´Ù: - Á¦Ç° À¯Çü: ÀÚº» Àåºñ - ÀÇ·á±â±â ¹× ¼Ò¸ðǰ - ¼Ö·ç¼Ç - ÀÓ»ó ÀÀ¿ë ºÐ¾ß: Á¾¾çÇÐ, ½ÉÀ庴ÇÐ, ½Å°æ¿Ü°ú, ºñ´¢±â°ú, Á¤Çü¿Ü°ú

¸ñÂ÷

¼ºÀå ±âȸ ºÐ¼®

  • ºÐ¼® ¹üÀ§
  • ¼¼ºÐÈ­

IGT ½ÃÀå º¯Çõ

  • ¿Ö ¼ºÀåÀÌ ¾î·Á¿öÁö°í Àִ°¡?
  • The Strategic Imperative 8(TM)
  • 3´ë Àü·«Àû °úÁ¦°¡ IGT »ê¾÷¿¡ ¹ÌÄ¡´Â ¿µÇâ

IGT ½ÃÀå »ýŰè

  • Á¤ÀÇ
  • Å©·Î½º ¸ð´Þ¸®Æ¼ À¶ÇÕÀ¸·Î¼­ÀÇ IGT
  • Ä¡·á ¸ð´Þ¸®Æ¼º° ¿µ»ó À¯µµ
  • ÁÖ¿ä IGT ¼Ö·ç¼Ç
  • IGT ¼­ºñ½º Á¦°ø¾÷ü À¯Çü
  • ÀÓ»ó ÀÀ¿ë ºÐ¾ßÀÇ ¹ßÀü
  • °æÀï ȯ°æ
  • ÁÖ¿ä °æÀï»ç

¼ºÀå Á¦³Ê·¹ÀÌÅÍ

  • ¼ºÀå ÁöÇ¥
  • ¼ºÀå ÃËÁø¿äÀÎ
  • ¼ºÀå ¾ïÁ¦¿äÀÎ
  • ¿¹Ãø¿¡ °üÇÑ ÀλçÀÌÆ®
  • ¸ÅÃâ ¿¹Ãø
  • Á¦Ç° À¯Çüº° ¸ÅÃâ ¿¹Ãø
  • Áö¿ªº° ¸ÅÃâ ¿¹Ãø
  • ÀÓ»ó ¿ëµµº° ¸ÅÃâ ¿¹Ãø
  • ¸ÅÃ⠺м®
  • ¸ÅÃâ Á¡À¯À²
  • ¸ÅÃâ Á¡À¯À² ºÐ¼®

¼ºÀå Á¦³Ê·¹ÀÌÅÍ : ºÏ¹Ì

  • ¼ºÀå ÁöÇ¥
  • ¸ÅÃâ ¿¹Ãø
  • Á¦Ç° À¯Çüº° ¸ÅÃâ ¿¹Ãø
  • ÀÓ»ó ¿ëµµº° ¸ÅÃâ ¿¹Ãø
  • ¿¹Ãø ºÐ¼®
  • IGT ¼Ö·ç¼ÇÀ» Æ÷ÇÔÇÑ ¹æ»ç¼± ¼Ö·ç¼Ç¿¡ °üÇÑ ¿¬¹æ ±ÔÁ¦
  • °æÀï ºÐ¼®

¼ºÀå Á¦³Ê·¹ÀÌÅÍ : À¯·´

  • ¼ºÀå ÁöÇ¥
  • ¸ÅÃâ ¿¹Ãø
  • Á¦Ç° À¯Çüº° ¸ÅÃâ ¿¹Ãø
  • ÀÓ»ó ¿ëµµº° ¸ÅÃâ ¿¹Ãø
  • ¿¹Ãø ºÐ¼®
  • IGT ¼Ö·ç¼ÇÀ» Æ÷ÇÔÇÑ ¹æ»ç¼± ¼Ö·ç¼Ç ÀÏ¹Ý µ¥ÀÌÅÍ º¸È£ ±ÔÄ¢(GDPR(EU °³ÀÎÁ¤º¸º¸È£±ÔÁ¤))
  • °æÀï ºÐ¼®

¼ºÀå Á¦³Ê·¹ÀÌÅÍ : ¾Æ½Ã¾ÆÅÂÆò¾ç

  • ¼ºÀå ÁöÇ¥
  • ¸ÅÃâ ¿¹Ãø
  • Á¦Ç° À¯Çüº° ¸ÅÃâ ¿¹Ãø
  • ÀÓ»ó ¿ëµµº° ¸ÅÃâ ¿¹Ãø
  • ¿¹Ãø ºÐ¼®
  • IGT ½ÃÀå ±âȸ·Î¼­ÀÇ ÀÇ·á°ü±¤
  • °æÀï ºÐ¼®

¼ºÀå Á¦³Ê·¹ÀÌÅÍ : ±âŸ Áö¿ª ½ÃÀå

  • ¼ºÀå ÁöÇ¥
  • ¸ÅÃâ ¿¹Ãø
  • Á¦Ç° À¯Çüº° ¸ÅÃâ ¿¹Ãø
  • ÀÓ»ó ¿ëµµº° ¸ÅÃâ ¿¹Ãø
  • ¿¹Ãø ºÐ¼®
  • °æÀï ºÐ¼®

ÀÓ»ó ÀÀ¿ë °³¿ä : ÀÀ¿ë Æ÷Ä¿½º - Á¾¾çÇÐ

  • Á¾¾çÇÐ Ä¡·á ¿É¼Ç
  • Àå±â º° ¿µ»ó À¯µµ ¹æ»ç¼± Ä¡·á¿Í ¹æ»ç¼± ¼ö¼ú
  • ¹æ»ç¼± Ä¡·á-°³¿ä
  • ¿µ»ó À¯µµÇÏ ±ÙÁ¢Ä¡·á(IGBT) - °³¿ä
  • ¼ö¼ú Áß ±ÙÁ¢Ä¡·á(IOBT)
  • ±â¾÷ ½ºÆ÷Æ®¶óÀÌÆ® : ElektaÀÇ Á¾¾çÇпë Á¦Ç°

ÀÓ»ó ÀÀ¿ë °³¿ä : ÀÀ¿ë Æ÷Ä¿½º - ½ÉÀ庴

  • ½ÉÀ庴 ÁÖ¿ä Ä¡·á ¿É¼Ç
  • ½ÉÀ庴 IXR ½ºÀ§Æ® »ç¿ë
  • X¼± °¡À̵åÇÏ IVUS ½Ã¼ú
  • ±â¾÷ ½ºÆ÷Æ®¶óÀÌÆ® : Boston Scientific CorporationÀÇ ½ÉÀ庴¿ë Á¦Ç°

ÀÓ»ó ÀÀ¿ë °³¿ä : ÀÀ¿ë Æ÷Ä¿½º - ½Å°æ³»°ú

  • ½Å°æ³»°ú Ä¡·á ¿É¼Ç
  • ½Å°æ³»°ú Ä¡·á ·Îµå¸Ê
  • ±â¾÷ ½ºÆ÷Æ®¶óÀÌÆ® : Koninklijke Philips N.V.ÀÇ Neuro Biplane Interventional System

ÀÓ»ó ÀÀ¿ë °³¿ä : ÀÀ¿ë Æ÷Ä¿½º - ºñ´¢±â°ú

  • IGT-ºñ´¢±â ÀÎÅͺ¥¼Ç
  • ±â¾÷ ½ºÆ÷Æ®¶óÀÌÆ® : GE HealthCareÀÇ 'bkActiv' ºñ´¢±â°ú¿ë Á¦Ç°

ÀÓ»ó ÀÀ¿ë °³¿ä : ÀÀ¿ë Æ÷Ä¿½º - Á¤Çü¿Ü°ú

  • IGT - Á¤Çü¿Ü°ú ÀÎÅͺ¥¼Ç
  • ±â¾÷ ½ºÆ÷Æ®¶óÀÌÆ® : Ziehm Imaging GmbHÀÇ Á¤Çü¿Ü°ú¿ë Á¦Ç°

¼ºÀå ±âȸ

  • ¼ºÀå ±âȸ 1 : ¿µ»ó À¯µµ Ä¡·á¸¦ À§ÇÑ ½Ç¼¼°è µ¥ÀÌÅÍ
  • ¼ºÀå ±âȸ 2 : ¸ÖƼ¸ð´Þ À̹Ì¡ ¿µ»ó À¯µµ °í°­µµ Áý¼Ó ÃÊÀ½ÆÄ »ç¿ë
  • ¼ºÀå ±âȸ 3 : ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ Àúħ½À ¼ö¼ú
  • ¼ºÀå ±âȸ 4 : ´ë·® ¼ö¼ú µ¥ÀÌÅ͸¦ °ü¸®Çϱâ À§ÇÑ Å¬¶ó¿ìµå ±â¹Ý Ç÷§Æû°ú AI ±â¹Ý ¼Ö·ç¼ÇÀÇ ÅëÇÕ

ºÎ·Ï°ú ´ÙÀ½ ´Ü°è

  • ¼ºÀå ±âȸÀÇ ÀÌÁ¡°ú ¿µÇâ
  • ´ÙÀ½ ´Ü°è
  • µµÇ¥
  • ¸éÃ¥»çÇ×
LSH 24.11.20

Increased Demand for Minimally Invasive Procedures and the Surge in Day Surgeries at Outpatient Facilities are Driving Transformational Growth

The image-guided therapy (IGT) market is growing rapidly, mainly driven by the rising preference for minimally invasive procedures, technological advancements in multimodal imaging, artificial intelligence, the use of software solutions that enable better clinical outcomes, and the high demand for precision medicine in oncology treatment. In addition, the IGT market is influenced by technological innovations in MRI, CT, molecular imaging, ultrasound, and interventional X-ray during oncology, cardiology, neurosurgery, orthopedic, and urology procedures. The integration of the aforementioned medical imaging modalities with navigation systems and robotics has enabled higher precision and accuracy during surgical procedures.

Frost & Sullivan expects IGT to sustain steady growth during the next 5 years, fueled by increasing expenditures and investments in research and development that drive market expansion. Frost & Sullivan also expects minimally invasive procedures to see higher adoption than conventional surgical procedures, which will propel IGT market growth.

The study period is from 2022 to 2029, the base year is 2024, and the forecast period is from 2025 to 2029. The study analyzes the North American, European, Asia-Pacific, and Rest of World markets, focusing on current scenarios, drivers and restraints, the latest technologies, and notable participants.

Frost & Sullivan segments the IGT market into the following categories: - Product type: - Capital equipment - Medical devices and consumables - Solutions - Clinical applications: oncology, cardiology, neurosurgery, urology, and orthopedics

Table of Contents

Growth Opportunity Analysis

  • Scope of Analysis
  • Segmentation

Transformation in the IGT Market

  • Why is it Increasingly Difficult to Grow?
  • The Strategic Imperative 8™
  • The Impact of the Top 3 Strategic Imperatives on the IGT Industry

Ecosystem in the IGT Market

  • Definition
  • IGT as a Cross-modality Convergence
  • Image Guidance by Therapeutic Modalities
  • Key IGT Solutions
  • IGT Service Provider Types
  • Developments in Clinical Application Areas
  • Competitive Environment
  • Key Competitors

Growth Generator

  • Growth Metrics
  • Growth Drivers
  • Growth Restraints
  • Forecast Considerations
  • Revenue Forecast
  • Revenue Forecast by Product Type
  • Revenue Forecast by Region
  • Revenue Forecast by Clinical Applications
  • Revenue Forecast Analysis
  • Revenue Share
  • Revenue Share Analysis

Growth Generator: North America

  • Growth Metrics
  • Revenue Forecast
  • Revenue Forecast by Product Type
  • Revenue Forecast by Clinical Applications
  • Forecast Analysis
  • Federal Regulations for Radiology Solutions, Including IGT Solutions
  • Competitive Analysis

Growth Generator: Europe

  • Growth Metrics
  • Revenue Forecast
  • Revenue Forecast by Product Type
  • Revenue Forecast by Clinical Applications
  • Forecast Analysis
  • GDPR for Radiology Solutions, Including IGT Solutions
  • Competitive Analysis

Growth Generator: APAC

  • Growth Metrics
  • Revenue Forecast
  • Revenue Forecast by Product Type
  • Revenue Forecast by Clinical Applications
  • Forecast Analysis
  • Medical Tourism as an Opportunity for the IGT Market
  • Competitive Analysis

Growth Generator: RoW

  • Growth Metrics
  • Revenue Forecast
  • Revenue Forecast by Product Type
  • Revenue Forecast by Clinical Applications
  • Forecast Analysis
  • Competitive Analysis

Overview of Clinical Applications: Application Focus-Oncology

  • Treatment Options for Oncology
  • Organ-specific Image-guided Radiotherapy andRadiosurgery
  • Radiation Therapy-Overview
  • Image-guided Brachytherapy (IGBT)-Overview
  • Intraoperative Brachytherapy (IOBT) Procedures
  • Company Spotlight: Elekta's Offerings for Oncology

Overview of Clinical Applications: Application Focus-Cardiology

  • Major Treatment Options for Cardiology
  • Use of IXR Suites in Cardiology
  • X-ray-guided IVUS Procedures
  • Company Spotlight: Boston Scientific Corporation's Offerings for Cardiology

Overview of Clinical Applications: Application Focus-Neurology

  • Treatment Options for Neurology
  • Roadmaps for Neurology Treatment
  • Company Spotlight: Koninklijke Philips N.V.'s Neuro Biplane Interventional System

Overview of Clinical Applications: Application Focus-Urology

  • IGT-Urology Interventions
  • Company Spotlight: GE HealthCare 's bkActiv for Urology Intervention

Overview of Clinical Applications: Application Focus-Orthopedics

  • IGT-Orthopedic Interventions
  • Company Spotlight: Ziehm Imaging GmbH's Offerings for Orthopedic Interventions

Growth Opportunity Universe

  • Growth Opportunity 1: Real-world Data for Image-guided Therapy
  • Growth Opportunity 2: Using Image-guided High-intensity Focused Ultrasound in Multimodal Imaging
  • Growth Opportunity 3: Minimally Invasive Procedures in APAC
  • Growth Opportunity 4: Integration of AI-based Solutions with Cloud-based Platforms to Manage Large Volumes of Surgical Data

Appendix & Next Steps

  • Benefits and Impacts of Growth Opportunities
  • Next Steps
  • List of Exhibits
  • Legal Disclaimer
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦